Linnane Projects

Linnane Projects is an Australian biotechnology company focused on the development of therapeutic interventions for respiratory and mitochondrial-related diseases. Founded by Professor Anthony Linnane, a pioneer in mitochondrial research, the company leverages its expertise in cellular energetics and oxidative stress to optimize existing compounds for new clinical applications. Its pipeline primarily features repurposed and optimized formulations of N-acetylcysteine (NAC) and bromhexine, targeting indications such as Cystic Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), and COVID-19. The company operates as part of the broader Linnane Pharma group, emphasizing clinical-stage research to address significant unmet medical needs in lung health. Through its clinical programs, Linnane Projects aims to improve patient outcomes by modulating inflammatory and oxidative pathways.